Cogent Biosciences (COGT) News Today $8.03 -0.10 (-1.23%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Average Price Target from AnalystsJanuary 19 at 4:13 AM | americanbankingnews.comShort Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Expands By 9.3%Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 7,980,000 shares, a growth of 9.3% from the December 15th total of 7,300,000 shares. Based on an average daily trading volume, of 1,430,000 shares, the short-interest ratio is presently 5.6 days.January 18 at 3:08 PM | marketbeat.comThis Cogent Biosciences Insider Increased Their Holding By 2,085% Last YearJanuary 18 at 1:53 PM | finance.yahoo.comHennion & Walsh Asset Management Inc. Buys 103,293 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Hennion & Walsh Asset Management Inc. boosted its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 60.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 275,292 shares of tJanuary 18 at 4:07 AM | marketbeat.comCogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST DataJanuary 18 at 4:02 AM | seekingalpha.comHC Wainwright Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $14.00January 17 at 3:13 AM | americanbankingnews.comCogent Biosciences up 10% at $8.14 after disclosing insider buyJanuary 16, 2025 | markets.businessinsider.comCogent and ModivCare gain after insider purchasesJanuary 15, 2025 | msn.comCogent Biosciences (NASDAQ:COGT) Shares Gap Up - Time to Buy?Cogent Biosciences (NASDAQ:COGT) Shares Gap Up - Here's WhyJanuary 15, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Price Target Lowered to $14.00 at HC WainwrightHC Wainwright dropped their price target on Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday.January 14, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Rating of "Moderate Buy" by BrokeragesShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued aJanuary 14, 2025 | marketbeat.comCogent Biosciences highlighted key 2025 milestonesJanuary 14, 2025 | markets.businessinsider.comWedbush Reiterates Neutral Rating for Cogent Biosciences (NASDAQ:COGT)Wedbush restated a "neutral" rating and set a $11.00 price target on shares of Cogent Biosciences in a report on Monday.January 13, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 11.9% - Here's WhyCogent Biosciences (NASDAQ:COGT) Stock Price Down 11.9% - What's Next?January 13, 2025 | marketbeat.comCogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted TherapeuticsJanuary 13, 2025 | markets.businessinsider.comCogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Shares Up 8.8% - Still a Buy?Cogent Biosciences (NASDAQ:COGT) Shares Up 8.8% - Here's WhyJanuary 6, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Down 2.5% - Time to Sell?Cogent Biosciences (NASDAQ:COGT) Trading Down 2.5% - Here's WhyDecember 31, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Holdings Trimmed by Jane Street Group LLCJane Street Group LLC trimmed its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 55.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 111,863 shares of the technology company's stock after selling 136,68December 30, 2024 | marketbeat.comGeode Capital Management LLC Purchases 300,062 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Geode Capital Management LLC raised its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 15.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,280,793 shares of the technology company's stock after acquiring an additional 300,0December 28, 2024 | marketbeat.comBarclays PLC Boosts Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Barclays PLC raised its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 124.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 175,684 shares of the technology company's stock afterDecember 27, 2024 | marketbeat.comState Street Corp Sells 605,500 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)State Street Corp cut its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 15.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,231,462 shares of the technology companyDecember 21, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four hDecember 20, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Down 4.4% - What's Next?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 4.4% - Time to Sell?December 18, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short InterestCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 8,420,000 shares, a growth of 9.1% from the November 15th total of 7,720,000 shares. Based on an average daily volume of 1,250,000 shares, the short-interest ratio is currently 6.7 days.December 16, 2024 | marketbeat.comHC Wainwright Has Negative Estimate for COGT FY2024 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Cogent Biosciences in a research report issued on Wednesday, December 11th. HC Wainwright analyst R. Burns now anticipates that the technology companyDecember 13, 2024 | marketbeat.comNeedham Downgrades Cogent Biosciences (COGT)December 12, 2024 | msn.comHC Wainwright Reiterates Buy Rating for Cogent Biosciences (NASDAQ:COGT)HC Wainwright restated a "buy" rating on shares of Cogent Biosciences in a report on Wednesday.December 11, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Rating Lowered by Needham & Company LLCNeedham & Company LLC lowered shares of Cogent Biosciences from a "buy" rating to a "hold" rating in a report on Wednesday.December 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Charles Schwab Investment Management Inc. lifted its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 20.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 825,793 shares of the tDecember 11, 2024 | marketbeat.comPromising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of BezuclasinibDecember 10, 2024 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $15.00 target price on shares of Cogent Biosciences in a research report on Monday.December 9, 2024 | marketbeat.comCogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsDecember 9, 2024 | globenewswire.comCogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)December 8, 2024 | globenewswire.comFmr LLC Has $89.85 Million Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Fmr LLC increased its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 8.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,319,411 shares of the technology company's stock after purchasing an addDecember 6, 2024 | marketbeat.comRedmile Group LLC Sells 315,593 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Redmile Group LLC decreased its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 6.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,484,380 shares of the technology company's stock after selling 315,593 shares during theDecember 5, 2024 | marketbeat.comBank of Montreal Can Invests $3.14 Million in Cogent Biosciences, Inc. (NASDAQ:COGT)Bank of Montreal Can purchased a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 287,610 shares of the technology companyDecember 5, 2024 | marketbeat.comWhy Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 4, 2024 | msn.comHighVista Strategies LLC Has $2.44 Million Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT)HighVista Strategies LLC cut its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 19.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 225,633 shares of the technology company's stock after selling 5December 3, 2024 | marketbeat.comCinctive Capital Management LP Buys 157,969 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Cinctive Capital Management LP increased its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 91.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,419 sharesDecember 3, 2024 | marketbeat.comWalleye Capital LLC Makes New Investment in Cogent Biosciences, Inc. (NASDAQ:COGT)Walleye Capital LLC bought a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 557,326 shares of the technology company's stock, valued atDecember 1, 2024 | marketbeat.comEventide Asset Management LLC Sells 479,357 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Eventide Asset Management LLC trimmed its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 34.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 919,635 shares of the technology company's stock aftNovember 30, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from AnalystsCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and fiveNovember 25, 2024 | marketbeat.comFY2024 EPS Forecast for Cogent Biosciences Lifted by AnalystCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Cogent Biosciences in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the technoNovember 18, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 7% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Trading Down 7% - Time to Sell?November 15, 2024 | marketbeat.comEquities Analysts Set Expectations for COGT FY2027 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Stock analysts at Leerink Partnrs raised their FY2027 earnings per share (EPS) estimates for Cogent Biosciences in a report released on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the technology company will eNovember 15, 2024 | marketbeat.comWhat is Lifesci Capital's Estimate for COGT FY2024 Earnings?Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at Lifesci Capital cut their FY2024 EPS estimates for shares of Cogent Biosciences in a note issued to investors on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky now anticipates that the technology company wilNovember 15, 2024 | marketbeat.comWedbush Reduces Earnings Estimates for Cogent BiosciencesCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at Wedbush decreased their FY2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the technology company wiNovember 15, 2024 | marketbeat.comCogent Biosciences: Promising Clinical Developments and Strategic Milestones Warrant a Buy RecommendationNovember 14, 2024 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Issues Earnings ResultsCogent Biosciences (NASDAQ:COGT - Get Free Report) issued its quarterly earnings results on Tuesday. The technology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same period in the prior year, the firm earned ($0.64) EPS.November 13, 2024 | marketbeat.com Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Media Mentions By Week COGT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COGT News Sentiment▼0.280.44▲Average Medical News Sentiment COGT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COGT Articles This Week▼133▲COGT Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunovant News Crinetics Pharmaceuticals News Avidity Biosciences News PTC Therapeutics News Rhythm Pharmaceuticals News Denali Therapeutics News Xenon Pharmaceuticals News ACADIA Pharmaceuticals News Vericel News MorphoSys News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COGT) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
